BOIRF:OTC-Boiron SA (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 43.90

Change

0.00 (0.00)%

Market Cap

USD 0.74B

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat ocular discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. It offers its products through distribution centers, pharmacy chains, wholesalers, supermarkets, drugstores, and health food stores. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Company Website : http://www.boiron.com

Address : 2, avenue de l?Ouest Lyonnais, Messimy, France, 69510

Employees : 3,500

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.65

52 Week High : 48.05

52 Week Low : 29.11

200 Day Moving Average : 44.42

50 Day Moving Average : 46.82

Shares Held By Insiders : 750.4%

Shares Held by Institutions : 8.76%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-22 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

-0.02 (-0.06%)

 USD74.96B 33.18 18.85
MKGAF MERCK Kommanditgesellschaft au..

+0.88 (+0.51%)

 USD74.47B 33.20 18.85
TKPHF Takeda Pharmaceutical Company ..

+1.65 (+4.77%)

 USD54.15B 21.31 0.12
ESALY Eisai Co., Ltd

-0.63 (-0.85%)

 USD21.16B 35.75 0.11
ESALF Eisai Co., Ltd

N/A

 USD20.89B 32.20 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

+0.06 (+1.27%)

 USD17.09B 28.05 3.61
SGIOY Shionogi & Co., Ltd

-0.08 (-0.58%)

 USD16.76B 2.08 0.08
SGIOF Shionogi & Co., Ltd

-0.30 (-0.54%)

 USD16.70B 16.74 0.08
TEVJF Teva Pharmaceutical Industries..

N/A

 USD13.34B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

 USD10.43B 79.00 0.21

ETFs Containing BOIRF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.64% 12% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.64% 12% F 14% F
Trailing 12 Months  
Capital Gain 25.07% 55% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.07% 54% F 58% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.33% 33% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.33% 33% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 24.43% 93% A 66% D
Risk Adjusted Return -70.94% 25% F 9% F
Market Capitalization 0.74B 86% B 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.59 34% F 43% F
Price/Book Ratio 1.42 59% F 54% F
Price / Cash Flow Ratio 14.63 8% F 13% F
EV/EBITDA 4.93 41% F 48% F
Management Effectiveness  
Return on Equity 8.55% 84% B 69% D+
Return on Invested Capital 9.50% 72% C- 69% D+
Return on Assets 9.06% 95% A 94% A
Debt to Equity Ratio 0.90% 68% D+ 79% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.65 67% D+ 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector